CHENZHOU ZIQI DONGLAI TRADING CO., LTD. – Trademark Portfolio

Entity Type: 99

CHENZHOU ZIQI DONGLAI TRADING CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include OOIRNICE. The owner is based in CHENZHOU, HUNAN.

ROOM 505, BUILDING 10, NO. 16 TONGXIN ROAD

BEIHU STREET, BEIHU DISTRICT

CHENZHOU, HUNAN 423000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

OOIRNICE
OOIRNICE
Registered 2024

Trademark Classifications

CHENZHOU ZIQI DONGLAI TRADING CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does CHENZHOU ZIQI DONGLAI TRADING CO., LTD. have?

CHENZHOU ZIQI DONGLAI TRADING CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does CHENZHOU ZIQI DONGLAI TRADING CO., LTD. file in?

CHENZHOU ZIQI DONGLAI TRADING CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CHENZHOU ZIQI DONGLAI TRADING CO., LTD.'s most well-known trademarks?

CHENZHOU ZIQI DONGLAI TRADING CO., LTD.'s registered trademark portfolio includes well-known marks such as OOIRNICE. These are among 1 currently registered trademark in the portfolio.

What is CHENZHOU ZIQI DONGLAI TRADING CO., LTD.'s trademark registration success rate?

CHENZHOU ZIQI DONGLAI TRADING CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.